http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
폐암 환자에서 면역조직화학 염색을 통한 p53, erbB-2, CEA 종양단백 발현과 임상적 의의
강동원 ( Dong Won Kang ),이규승 ( Gyu Seung Lee ),김선영 ( Sun Young Kim ),김주옥 ( Ju Ock Kim ),정성수 ( Seong Su Jeong ),고동석 ( Dong Seok Ko ),서재철 ( Jae Chul Suh ),김근화 ( Geun Hwa Kim ),신경상 ( Kyoung Sang Shin ),송규상 대한결핵 및 호흡기학회 1998 Tuberculosis and Respiratory Diseases Vol.45 No.4
Toll-Like Receptor 2 유전자의 Microsatellite 유전자 다형성과 만성폐쇄성폐질환 발생과의 연관성 결여
이희석 ( Hee Seok Lee ),이혜원 ( Hye Won Lee ),김덕겸 ( Deog Kyeom Kim ),고동석 ( Dong Seok Ko ),박근민 ( Gun Min Park ),황용일 ( Yong Il Hwang ),이상민 ( Sang Min Lee ),유철규 ( Chul Gyu Yoo ),김영환 ( Young Whan Kim ),한성구 ( S 대한결핵 및 호흡기학회 2005 Tuberculosis and Respiratory Diseases Vol.58 No.4
김선영(sun Young Kim),신경상(Kyoung Sang Shin),고동석(Dong Seok Ko),서재철(Jae Cheol Seo),김근화(Geun Hwa Kim),정성수(Seong Su Jeong),박상기(Sang Ki Park),김주옥(Ju lck Kim) 대한내과학회 1998 대한내과학회지 Vol.55 No.1
N/A Objectives : Tuberculous cervical lymphadenitis is one of the common cause of cervical mass in young adult in Korea. Sometimes it appears to be difficult in defining the role of surgery and duration of antituberculous treatment. To clarify the duration of medical treatment and to define the cause of prolonged treatment duration Methods : we analyzed the clinical data of 62 patients with tuberculous cervical lymphadenitis diagnosed at the Chungnam National University Hospital from Jan. 1994 to July 1996 and all patients were divided into two groups (standard and prolonged) by treatment duration. Results : The most prevalent age group was 20 to 39 years old (67%) and male to female ratio was 1:2.6 The most common physical finding was painless swelling on neck, standard group was 52%, prolonged group was 42%. The average size of lymph node was 2.7cm and 3.2cm, respectively (p<0.05). In prolonged group, incidence of associated pulmonary tuberculosis and previous antituberculous treatment history were higher than that in standard group (27%, 35% respectively). The most common affected site was right side of neck, whereas 19% of prolonged regimen group were involved in both side of neck. Bacteriological study from node aspirates showed relatively higher positivity in prolonged group (27%) than in standarded group (5%). The causes of prolonged treatment were increased mass(27%) or remnant mass(23%) and the develoment of new node formation and existing nodes after completion of treatment were found in both groups(10% of standard group, 19% of prolonged group). Conclusion : A new, prospective trial for proper regimens or duration of antituberculosis treatment is strongly needed.
폐결핵 진단을 위한 STAT-PAK ULTRA FAST(R)와 ICT Tuberculosis(R)의 유용성에 관한 연구
김근화 ( Geun Hwa Kim ),박희선 ( Hee Sun Park ),김명훈 ( Myung Hoon Kim ),강동원 ( Dong Won Kang ),이규승 ( Kyu Seung Lee ),고동석 ( Dong Seok Ko ),서재철 ( Jae Chul Suh ),정성수 ( Seong Su Jeong ),김주옥 ( Ju Ock Kim ),김선영 ( S 대한결핵 및 호흡기학회 1999 Tuberculosis and Respiratory Diseases Vol.47 No.3
항산균 도말 검사, 세포진 검사가 음성이고, ADA와 CEA가 낮은 림프구성 흉막 삼출증의 임상 양상과 예후
강영애 ( Young Ae Kang ),윤영순 ( Young Soon Yoon ),이세원 ( Sei Won Lee ),최창민 ( Chang Min Choi ),김덕겸 ( Deog Kyeom Kim ),이희석 ( Hee Seok Lee ),고동석 ( Dong Seok Ko ),유철규 ( Chul Gyu Yoo ),김영환 ( Young Whan Kim ),한성 대한결핵 및 호흡기학회 2005 Tuberculosis and Respiratory Diseases Vol.58 No.1
연구 배경 : 흉수의 항산균 도말과 세포진 검사가 음성이며, 흉수의 ADA 가 40 IU/L 이하, CEA가 10ng/ml 이하인 림프구성 흉막 삼출증의 임상적 특징과 예후를 살펴보고자 한다. 연구 방법 : 2000년 1월 1일부터 2001년 8월 31일 사이에 서울대학교 병원을 방문한 림프구성 흉막 삼출증 환자들 중 흉수의 항산균 도말과 세포진 검사가 음성이며, 흉수의 ADA가 40 IU/L 이하, CEA가 10ng/ml 이하인 환자들의 의무 기록을 Background : A pleural effusion is a common medical problem. Despite several diagnostic tests, 15-20% of pleural effusions go undiagnosed. The aim of this study was to evaluate the clinical characteristics and prognosis of a lymphocyte dominant exudative
고동석,김명훈,박희선,강동원,이규승,서재철,김근화,정성수,김주옥,김선영 충남대학교 의과대학 지역사회의학연구소 2000 충남의대잡지 Vol.27 No.2
Background: Chemotherapy and radiotherapy have been main treatment methods of small cell lung cancer(SCLC). Recently, however, surgical therapy applied to SCLC stage I and II according to the TNM stage system. Veterans Administration Lung Cancer Study Group(VALG) for SCLC have combined limited- and extensive-stage that have not included anatomic staging information. We performed this study to examine the possible benefit of TNM staging included anatomic staging information in the SCLC. Method: We retrospectively reviewed medical records and computed tomography (CT) of 157 patients (133 men and 15 women: median age, 60 years: range, 33-78 years) with small cell lung cancer (SCLC). The survival according to TNM stage and classification of Veterans Administration Lung Cancer Study Group (VALG) was analyzed. Results: Eighty two patients had extensive stage (ES) and 75 patients had limited stage (LS). The median survival of each stage was 390 days and 300 days (p<0.05). Three patients had Stage la, 5 patients, stage Ib; 0 patients, stage Ila; 11 patients, stage IIb; 32 patients, stage IIIa; 42 patients, stage IIIb; 64 patients, stage IV. The median survival of patients according to TNM staging system was 1022 days in stage Ib, 425 days in stage IIb, 396 days in stage IIIa, 390 days in stage IIIb, and 240 days in stage IV Conclusion: Revised TNM stage system included anatomic staging information is useful to estimate prognosis and survival of SCLC.
IIIA 병기의 비소세포 폐암 환자에서 술전 유도화학요법의 임상적 효과
강동원,이규승,김선영,김주옥,정성수,고동석,서재철,김근화 대한내과학회 1999 대한내과학회지 Vol.57 No.2
Background: Surgical therapy remains the only curative treatment of localized non-small cell lung cancer(NSCLC). But the efficacy of surgery for patients with NSCLC is limited, although recent studies suggest that neoadjuvant chemotherapy may improve survival. Many studies also demonstrated benefit for neoadjuvant therapy. However very few studies about neoadjuvant chemotherapy were reported in Korea. We conducted this study to examine the possible benefit of neoadjuvant chemotherapy in patients with operable stage IIIA NSCLC. Methods : Twenty seven patients(25 men and 2 women) with clinical stage IIIA NSCLC were analyzed. The patients received 2 to 4 courses of cisplatin based chemotherapy and followed by surgery. To compare the resection rate and survival, 12 patients(10 men, 2 women) with clinical stage IIIA and initially treated operation were also anayzed. Results: The radiologically assessed response rate to the neoadjuvant therapy was 59.3%. Twelve seven patients underwent gross tumor resection with 24(88.9%) having complete resection and 21(77.8%) having postaperative stage I ar II. Pathologically defined response in nodal staging was more higher(85.2%). There was no difference of relapse free interval in recurred patients between two groups. But in patients treated with neoadjuvant therapy, distant recurrence is less higher than local recurrence. The median period of survival was 42 months in the patients treated with neoadjuvant therapy, and 27 months in the patients initially treated with surgery(p=0.287). Conclusion : The neoadjuvant chemotherapy improves local tumor control and lowers the distant recurrence. There was a possible trend improving median survival. So neoadjuvant chemotherapy might be considered as a standard therapy in stage IIIA NSCLC.